The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

Basit Öğe Kaydı
dc.contributor.authorAlmuradova, Elvina
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorArak, Hacı
dc.contributor.authorTamer, Fatih
dc.contributor.authorKefeli, Umut
dc.contributor.authorKoca, Sinan
dc.contributor.authorSen, Erdem
dc.date.accessioned2024-11-07T10:39:36Z
dc.date.available2024-11-07T10:39:36Z
dc.date.issued2024
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractMetastatic castration-resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed to assess the activity and tolerability of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT) in mCRPC patients across multiple cancer centers in Turkey. The study included 165 patients who received at least one cycle of Lu-177 PSMA-617 RLT, with the majority having bone metastases and undergone prior treatments. Prostate-specific antigen (PSA) levels were assessed before each treatment cycle, and the biochemical response was evaluated in accordance with the Prostate Cancer Work Group 3 Criteria. The PSA decline of ?50% was classified as a response, while an increase of ?25% in PSA levels was indicative of progressive disease. Neither response nor progression was considered as stable disease. The Lu-177 PSMA-617 RLT led to a significant PSA response, with 50.6% of patients achieving a >50% decrease in PSA levels. Median overall survival (OS) and progression-free survival were 13.5 and 8.2 months, respectively. Patients receiving Lu-177 PSMA-617 RLT in combination with androgen receptor pathway inhibitors (ARPIs) had a higher OS compared to those receiving Lu-177 PSMA-617 RLT alone (18.2 vs 12.3 months, P =.265). The treatment was generally well-tolerated, with manageable side effects such as anemia and thrombocytopenia. This study provides real-world evidence supporting the effectiveness and safety of Lu-177 PSMA-617 RLT in mCRPC patients, particularly when used in combination with ARPIs. These findings contribute to the growing body of evidence on the potential benefits of PSMA-targeted therapies in advanced prostate cancer. © 2023 UICC.
dc.identifier.doi10.1002/ijc.34749
dc.identifier.endpage700
dc.identifier.issn0020-7136
dc.identifier.issue4
dc.identifier.pmid37818966
dc.identifier.scopus2-s2.0-85173707223
dc.identifier.scopusqualityQ1
dc.identifier.startpage692
dc.identifier.urihttps://doi.org/10.1002/ijc.34749
dc.identifier.urihttps://hdl.handle.net/11480/11061
dc.identifier.volume154
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofInternational Journal of Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectlutetium-177
dc.subjectprostate cancer
dc.subjectPSMA-617
dc.subjectradioligand therapy
dc.titleThe real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu